ACT-293987 in Pulmonary Arterial Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 709 participants.

Also called NCT01112306

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 709 participants (enrolled count) (from the registry)
Sponsor
  • Actelion Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01112306
  • EudraCT 2009-014992-31
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Belarus, Belgium, Canada, Chile, China, Colombia, Czechia, Denmark, France, Germany, Greece, Hungary, India, Ireland, Israel, Malaysia, Mexico, Netherlands, Peru, Poland, Romania, Russia, Serbia, Singapore, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01112306. Allocation not applicable; no masking; primary purpose treatment. Start 2010-07-07 (actual); primary completion 2021-08-26 (actual). Results posted on 2022-09-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ACT-293987 in Pulmonary Arterial Hypertension
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
ACT-293987
Lead sponsor
Actelion (class: industry)

Record details

Record id
cardio:ct-nct01112306
Content hash
fd49496460f78231fadee783aeb83f28867b06f7205b70632f9173ba3c64a836